DK1702618T3 - Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer - Google Patents

Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer

Info

Publication number
DK1702618T3
DK1702618T3 DK06011784T DK06011784T DK1702618T3 DK 1702618 T3 DK1702618 T3 DK 1702618T3 DK 06011784 T DK06011784 T DK 06011784T DK 06011784 T DK06011784 T DK 06011784T DK 1702618 T3 DK1702618 T3 DK 1702618T3
Authority
DK
Denmark
Prior art keywords
dexamethasone
cancer
treatment
combination therapy
therapy
Prior art date
Application number
DK06011784T
Other languages
Danish (da)
English (en)
Inventor
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Esteban Cvitkovic
George Daniel Demetri
Chris Twelves
Hoff Daniel D Von
Jean-Louis Misset
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of DK1702618T3 publication Critical patent/DK1702618T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06011784T 1999-05-13 2000-05-15 Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer DK1702618T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer

Publications (1)

Publication Number Publication Date
DK1702618T3 true DK1702618T3 (da) 2008-02-25

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00927584T DK1176964T3 (da) 1999-05-13 2000-05-15 Brug af ET743 til behandling af cancer
DK06014005.0T DK1716853T3 (da) 1999-05-13 2000-05-15 Behandling af cancer i menneskekroppen ved anvendelse af ET743
DK06011784T DK1702618T3 (da) 1999-05-13 2000-05-15 Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK00927584T DK1176964T3 (da) 1999-05-13 2000-05-15 Brug af ET743 til behandling af cancer
DK06014005.0T DK1716853T3 (da) 1999-05-13 2000-05-15 Behandling af cancer i menneskekroppen ved anvendelse af ET743

Country Status (32)

Country Link
US (1) US8119638B2 (xx)
EP (3) EP1702618B1 (xx)
JP (2) JP2002544231A (xx)
KR (1) KR20020019914A (xx)
CN (2) CN1360503A (xx)
AR (1) AR028476A1 (xx)
AT (3) ATE338552T1 (xx)
AU (2) AU777417B2 (xx)
BG (1) BG65680B1 (xx)
BR (1) BR0010531A (xx)
CA (1) CA2373794C (xx)
CY (4) CY1105818T1 (xx)
CZ (1) CZ301482B6 (xx)
DE (4) DE122008000013I1 (xx)
DK (3) DK1176964T3 (xx)
ES (2) ES2294756T3 (xx)
FR (1) FR08C0013I2 (xx)
HU (2) HU229866B1 (xx)
IL (2) IL146434A0 (xx)
LU (1) LU91418I2 (xx)
MX (1) MXPA01011562A (xx)
MY (1) MY164077A (xx)
NL (1) NL300337I2 (xx)
NO (2) NO324564B1 (xx)
NZ (1) NZ515423A (xx)
PL (1) PL198185B1 (xx)
PT (3) PT1716853E (xx)
SI (3) SI1702618T1 (xx)
SK (1) SK287580B6 (xx)
TR (1) TR200103819T2 (xx)
UA (1) UA74782C2 (xx)
WO (1) WO2000069441A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
BRPI0517238B1 (pt) 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
BR112018015118A2 (pt) * 2016-02-04 2018-12-18 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica injetável inclusiva de trabectedina para uso externo gastrointestinal e método de fabricação da mesma
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
HRP20240766T1 (hr) 2020-04-15 2024-09-13 Ever Valinject Gmbh Pripravak koji sadrži trabektedin i aminokiselinu
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
ATE69234T1 (de) * 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
JPH09503743A (ja) * 1993-05-14 1997-04-15 デポテック コーポレーション 神経学的疾患の治療方法
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DK1586322T3 (da) * 1996-11-05 2008-12-01 Childrens Medical Center Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
EP1876180A3 (en) * 1998-04-06 2009-12-16 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
CZ302168B6 (cs) * 1998-05-11 2010-11-24 Pharma Mar, S. A. Metabolity ecteinascidinu 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2418320A1 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
BR0115162A (pt) 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
EP1372658A2 (en) 2001-03-30 2004-01-02 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005261860A1 (en) 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
BRPI0517238B1 (pt) 2004-10-29 2021-11-09 Pharma Mar, S.A. Composições que compreendem ecteinascidina e um dissacarídeo, método para produzir um frasco que contém a referida composição e para preparar uma solução para infusão intravenosa e uso da referida solução
ES2361566T3 (es) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
CA2652035A1 (en) 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
CA2373794A1 (en) 2000-11-23
EP1716853B9 (en) 2011-09-28
EP1176964B1 (en) 2006-09-06
AU777417B2 (en) 2004-10-14
SK16442001A3 (sk) 2002-03-05
WO2000069441A1 (en) 2000-11-23
HUS1500001I1 (hu) 2016-08-29
SI1702618T1 (sl) 2008-02-29
TR200103819T2 (tr) 2002-04-22
US8119638B2 (en) 2012-02-21
NL300337I1 (nl) 2008-05-01
DK1176964T3 (da) 2007-01-15
CN1679631A (zh) 2005-10-12
FR08C0013I2 (fr) 2009-10-30
HU229866B1 (en) 2014-10-28
DE60030554D1 (de) 2006-10-19
MY164077A (en) 2017-11-30
DK1716853T3 (da) 2011-06-27
NO20015516D0 (no) 2001-11-12
CY1105818T1 (el) 2011-02-02
ATE500830T1 (de) 2011-03-15
EP1716853A2 (en) 2006-11-02
DE60036826D1 (de) 2007-11-29
DE60045720D1 (de) 2011-04-21
EP1702618A3 (en) 2006-12-27
CY1112753T1 (el) 2016-02-10
AU2005200180A1 (en) 2005-02-10
UA74782C2 (uk) 2006-02-15
CA2373794C (en) 2005-10-11
KR20020019914A (ko) 2002-03-13
CN100477993C (zh) 2009-04-15
NO20015516L (no) 2002-01-11
SI1716853T1 (sl) 2011-10-28
BR0010531A (pt) 2002-06-04
CZ20014081A3 (cs) 2002-11-13
CY2008007I2 (el) 2009-11-04
NO324564B1 (no) 2007-11-19
EP1716853B1 (en) 2011-03-09
JP5777562B2 (ja) 2015-09-09
CN1360503A (zh) 2002-07-24
BG106171A (en) 2002-06-28
EP1176964A1 (en) 2002-02-06
AU2005200180B2 (en) 2007-12-13
DE60036826T2 (de) 2008-08-28
LU91418I9 (xx) 2019-01-02
PT1176964E (pt) 2007-01-31
SI1176964T1 (sl) 2007-02-28
BG65680B1 (bg) 2009-06-30
IL146434A0 (en) 2002-07-25
PT1716853E (pt) 2011-05-12
PT1702618E (pt) 2008-01-11
ES2272279T3 (es) 2007-05-01
US20070275942A1 (en) 2007-11-29
DE60030554T2 (de) 2007-09-13
JP2002544231A (ja) 2002-12-24
LU91418I2 (fr) 2008-05-13
AR028476A1 (es) 2003-05-14
ATE338552T1 (de) 2006-09-15
AU4597500A (en) 2000-12-05
AU2005200180B9 (en) 2008-05-29
CY1107143T1 (el) 2010-07-28
DE122008000013I1 (de) 2008-08-07
EP1702618B1 (en) 2007-10-17
PL198185B1 (pl) 2008-06-30
ES2294756T3 (es) 2008-04-01
NL300337I2 (nl) 2008-09-01
FR08C0013I1 (xx) 2008-05-30
JP2012149095A (ja) 2012-08-09
SK287580B6 (sk) 2011-03-04
IL146434A (en) 2008-03-20
DE60030554T8 (de) 2008-01-10
PL352931A1 (en) 2003-09-22
HUP0201187A3 (en) 2002-11-28
EP1716853A3 (en) 2006-11-15
EP1702618A2 (en) 2006-09-20
NZ515423A (en) 2004-04-30
EP1176964B8 (en) 2007-10-10
ATE375795T1 (de) 2007-11-15
MXPA01011562A (es) 2002-07-30
NO2008005I1 (no) 2008-06-09
CY2008007I1 (el) 2009-11-04
NO2008005I2 (xx) 2010-09-27
CZ301482B6 (cs) 2010-03-17
HUP0201187A2 (en) 2002-09-28

Similar Documents

Publication Publication Date Title
DK1702618T3 (da) Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer
EE200100480A (et) Ksenoon kasutamiseks närvimürgistuste ravis
NO20022174L (no) Anvendelse av anti-CD40L-antistoff i kombinasjon med anti- CD20-antistoff og/eller kjemoterapeutika og radioterapi vedbehandling av B-cellesykdommer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
DE60020327D1 (de) Wasserbehandlungsvorrichtung
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
FI20000863A (fi) Uusi hoitomenetelmä
DE60040607D1 (de) Wasserbehandlungseinrichtung
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
NO20022245L (no) Onkolyttiske kombinasjoner for behandling av cancer
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
DK1165071T3 (da) Forbedret cancerbehandling med temozolomid
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
NO20020008D0 (no) Anvendelse av cortisol antagonister i behandling av hjertesvikt
ATE302165T1 (de) Wasserbehandlung
NO20014228L (no) Radioaktiv cisplatin i behandling av cancer
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
EE200200348A (et) Ravimkoostis kasutamiseks valu ravis
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
FI20002612A0 (fi) Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
ES1044621Y (es) Tumbona perfeccionada